Skip to Main content Skip to Navigation
Journal articles

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer

Emeric Boisteau 1 Alexandra Lespagnol 1 Marie de Tayrac 2, 1 Sébastien Corre 2 Anthony Perrot 1 Nathalie Rioux-Leclercq 1, 3 Séverine Martin-Lannerée 4 Pascal Artru 5 Philippe Chalabreysse 6 Pierre-Guillaume Poureau 7 Laurent Doucet 8 Dahna Coupez 9, 10 Jaafar Bennouna 9, 10 Céline Bossard 10 Romain Coriat 11 Frédéric Beuvon 11 Lucile Bauguion 12 François Leclair 12 Romain Chautard 13 Thierry Lecomte 13, 14 Serge Guyetant 13, 15 Romain Desgrippes 16 Denis Grasset 17 Hélène Lhostis 17 Karine Bouhier-Leporrier 18 Frédéric Bibeau 18 Julien Edeline 19, 20 Marie-Dominique Galibert 2, 1, * Astrid Lièvre 1, 21, 22, * 
Abstract : BACKGROUND: Low miR-31-3p expression was identified as predictive of anti-EGFR efficacy in RAS-wt mCRC. Primary tumor side was also proposed as a predictive factor of anti-EGFR benefit. This retrospective multicentric study evaluated the predictive role of miR-31-3p in right-sided RAS-wt mCRC patients treated with first-line CT+anti-EGFR or CT+bevacizumab (Beva). METHODS: Seventy-two right-sided RAS-wt mCRC patients treated in first-line with CT+anti-EGFR (n=43) or Beva (n=29) were included. Overall survival (OS), progression-free survival (PFS) and response rate (RR) were analyzed and stratified according to tumor miR-31-3p expression level and targeted therapy (TT). RESULTS: BRAF V600E mutation was more frequent in high vs low miR-31-3p expressers (60.6% vs 15.4%, P < 0.001). PFS was significantly longer with CT+Beva than with CT+anti-EGFR (13 vs 7 months; P = 0.024). Among low miR-31-3p expressers, PFS, OS and RR were not significantly different between the two groups, while in high miR-31-3p expressers, only PFS was longer in the CT+Beva group (11 vs 6 months; P = 0.03). In patients treated with CT+anti-EGFR, low miR-31-3p expressers had a significantly longer OS (20 vs 13 months; P = 0.02) than high miR-31-3p expressers. ORR was not significantly different between the two groups of treatment, in both low and high miR-31-3p expressers. MiR-31-3p expression status was statistically correlated between primary tumors and corresponding metastases. CONCLUSION: In this study, miR-31-3p couldn’t identify a subgroup of patients with right-sided RAS-wt mCRC who might benefit from anti-EGFR and suggest that Beva is the TT of choice in first-line treatment of these patients.
Complete list of metadata
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Friday, April 1, 2022 - 10:15:17 AM
Last modification on : Thursday, June 9, 2022 - 5:24:44 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-08-18

Please log in to resquest access to the document


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License



Emeric Boisteau, Alexandra Lespagnol, Marie de Tayrac, Sébastien Corre, Anthony Perrot, et al.. MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer. Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2022, 46 (5), 11 p. ⟨10.1016/j.clinre.2022.101888⟩. ⟨hal-03595901⟩



Record views